A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection

BACKGROUND & AIMS: In Taiwan, patients with chronic hepatitis C virus (HCV) infection are currently treated with pegylated interferon‐alpha plus ribavirin, but interferon‐based regimens can be poorly tolerated, especially by those with advanced liver disease and the elderly. Sofosbuvir, an oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Kao, Jia‐Horng, Chien, Rong‐Nan, Chang, Ting‐Tsung, Peng, Cheng‐Yuan, Hu, Tsung‐Hui, Lo, Gin‐Ho, Wang, Horng‐Yuan, Chen, Jyh‐Jou, Yang, Jenny C., Knox, Steven J., Han, Lingling, Mo, Hongmei, Mathias, Anita, Brainard, Diana M., Sheen, I‐Shyan, Hsu, Yu‐Chun, Chu, Chi‐Jen, Chuang, Wan‐Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Viral Hepatitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071670/
https://www.ncbi.nlm.nih.gov/pubmed/26835876
http://dx.doi.org/10.1111/liv.13082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071670/
https://www.ncbi.nlm.nih.gov/pubmed/26835876
http://dx.doi.org/10.1111/liv.13082

Ejemplares similares